Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.
about
Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cellsBOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cellsDiscovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activitySteroidogenesis in the skin: implications for local immune functionsEmerging therapies for severe asthmaEvaluation of the selective glucocorticoid receptor agonist compound A for ototoxic effectsAntiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoidsGlucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex.What's new in atopic eczema?Recent advances in the development of novel glucocorticoid receptor modulators.The multiple facets of glucocorticoid action in rheumatoid arthritis.Newer glucocorticosteroids and corticosteroid resistance reversal in asthma.What is new in atopic dermatitis/eczema?Glucocorticoid receptor function in health and disease.The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy.Emerging corticosteroid agonists for the treatment of asthma.Novel glucocorticoid receptor agonists in the treatment of asthma.Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profileTest systems for the determination of glucocorticoid receptor ligand induced skin atrophy.Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.Anti-inflammatory effects of mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by MAP kinase phosphatase-1 (MKP-1).Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist.Anti-inflammatory effects of selective glucocorticoid receptor modulators are partially dependent on up-regulation of dual specificity phosphatase 1Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy.The transrepression arm of glucocorticoid receptor signaling is protective in mutant huntingtin-mediated neurodegeneration.Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin.Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis.Safer topical treatment for inflammation using 5α-tetrahydrocorticosterone in mouse models.Mediators and receptors in the resolution of inflammation: drug targeting opportunities.Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cellsCrystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads.Glucocorticoid-Induced Osteoporosis.The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs.A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation
P2860
Q24619895-F6E27613-C202-4232-B4F9-50D8DA1923D1Q24644700-D772262C-636A-4FAD-9A97-F6D991B72F1DQ26782111-34DE4CC7-DFE0-49A2-AB0B-EF01C007C333Q26830355-269FD234-3328-4B50-B7F6-AB8C2512E976Q26861260-3D831F46-F9D2-4B9F-928C-F87DD4D0BAC9Q30382813-F41EC257-04AE-4ADE-834A-119309C60E08Q33670387-15CDB547-4672-4BA5-BCB2-40F6F53EE6B5Q34548430-559E703F-CBDB-4CDA-96D3-5D10E4AF604FQ35023858-5DEB4000-6DEC-428D-937B-DDFCAAD9B175Q36563476-C7CB5AEB-FBEC-41DD-B8A6-A4A9C9F0AB5DQ37740142-DC414653-4E0B-499D-90E2-FE7BD7B15D44Q37765564-C1CD527B-6099-44AC-A973-483BFA40C993Q38050401-545D106B-A9DC-445C-A0E3-3EAF4919CB96Q38162976-8FCC621D-1799-436E-B381-5A00FE7E6FB0Q38257104-6EE132C4-2038-41C3-8831-F8DD334447E9Q38334937-7AA66B92-213F-45F1-9FB8-599BB7C660BAQ38436495-5F8FF835-CEE5-4403-9166-8F221E64E126Q38537176-A2249D6E-1E61-418B-82E0-CFA934A8774CQ38570469-B61C662B-7A28-4271-A4AC-5044EFA9CD72Q39157135-33F8B81E-D5E2-4972-A914-271F5E0B3F3EQ39194377-3319336C-F13A-4109-B0F7-3280F57B69B0Q39223255-784BDCD9-32B6-4F50-8BCA-C5FA8DE08F9CQ39296353-96462414-21C1-4509-987F-3D17F6936C44Q39423430-8285D36E-92AA-4140-ABC7-950F1E6B4BECQ39515328-B95F30E1-0373-4BC8-A6DD-61D306F5B6BEQ40816092-35D3B404-F074-4A38-9D03-D90B633123C5Q41244698-7CF48AA2-5770-422E-9892-C557DF2D8FC6Q41282756-CF2BFEDB-B676-4984-B271-995FD92D549FQ42131163-D8F10A9B-CE29-4F54-8888-DB544C47D20FQ42317457-A7C4D4DB-6D69-47DB-9B26-FC8283C74B82Q42681904-035654CB-4E8A-47BC-B138-4FF31EC31440Q42743183-1F771635-6158-4434-A5BB-0ABAA4C875A5Q44358992-5A32A4B7-0C1D-401D-8E08-760E711CFE03Q47145773-CD66D35E-476E-4E08-91EC-BEE49238BB0DQ51093091-1C62E292-A7B0-4EC4-9C2C-278B05F6042CQ51636312-DA54CF6A-07EE-41F3-A472-CC940511A95AQ57203553-02DCE76C-1EF2-4E5C-9A01-F0885B1DFDFE
P2860
Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@en
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@nl
type
label
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@en
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@nl
prefLabel
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@en
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@nl
P2093
P2860
P1476
Characterization of ZK 245186, ...... of inflammatory skin diseases.
@en
P2093
H Rehwinkel
K Asadullah
T M Zollner
W Skuballa
P2860
P304
P356
10.1111/J.1476-5381.2009.00238.X
P407
P577
2009-05-06T00:00:00Z